Author at Microdose

Emma Stone

Hi there! I'm a journalist specializing in cannabis and psychedelics. I also hold a PhD in sociology, which has served me well when it comes to researching scholarly material and communicating it in an engaging, accessible way. I'd welcome the opportunity to contribute to Microdose on a regular basis, and have included some relevant recent samples of my writing below. Looking forward to hearing from you, Warmly, Emma

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Science

7 Dec 2022

Tripping Without The Trip: Non-Hallucinogenic Psychedelics

What happens if you remove the trip from psychedelic experiences? Do non-hallucinogenic psychedelic experiences give the same therapeutic advantages?...

By Emma Stone

Law & Politics

24 Nov 2022

Right-to-Try Psilocybin: Legal Battle With DEA Continues

Two years ago, Dr....

By Emma Stone

Law & Politics

15 Nov 2022

Alberta’s Psychedelic Therapy Laws: What Are the Implications?

Alberta made history on October 5th, 2022 when the government became the first province in Canada to regulate psychedelic therapy....

By Emma Stone

Science

18 Oct 2022

Can LSD Make You Smarter? New Study Shows Positive Results

Humans are always on the hunt for life hacks, whether it’s getting fitter, slimmer, or more beautiful....

By Emma Stone

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture, Industry

15 Sep 2022

New Survey Shows Psychedelic Use At Record High

While enthusiastic researchers, psychonauts and high-profile influencers sing the praises of psychedelics, how do everyday people interact with these once-stigmatized substances? How has the growing momentum of the psychedelic renaissance...

By Emma Stone

Industry, Science

25 Aug 2022

Anchoring Peak Experience: The World’s First Study of VR and Psychedelics

Virtual Reality and Psychedelics: A new frontier in mind medicine?...

By Emma Stone

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Hi there! I'm a journalist specializing in cannabis and psychedelics. I also hold a PhD in sociology, which has served me well when it comes to researching scholarly material and communicating it in an engaging, accessible way. I'd welcome the opportunity to contribute to Microdose on a regular basis, and have included some relevant recent samples of my writing below. Looking forward to hearing from you, Warmly, Emma

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads